What is Roth Capital’s Forecast for Cryoport Q2 Earnings?

Cryoport, Inc. (NASDAQ:CYRX) – Equities research analysts at Roth Capital lifted their Q2 2025 earnings estimates for shares of Cryoport in a research report issued to clients and investors on Thursday, May 8th. Roth Capital analyst R. Baldry now forecasts that the company will earn ($0.26) per share for the quarter, up from their previous forecast of ($0.30). The consensus estimate for Cryoport’s current full-year earnings is ($0.99) per share. Roth Capital also issued estimates for Cryoport’s Q3 2025 earnings at ($0.25) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.96) EPS, Q1 2026 earnings at ($0.22) EPS, Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.83) EPS.

Cryoport (NASDAQ:CYRX) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.01. Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The firm had revenue of $41.04 million during the quarter, compared to the consensus estimate of $56.19 million.

A number of other analysts also recently commented on the stock. Roth Mkm reiterated a “buy” rating and issued a $15.00 price objective on shares of Cryoport in a report on Tuesday, April 1st. UBS Group increased their price objective on shares of Cryoport from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, April 1st. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of Cryoport in a report on Thursday, May 8th. Morgan Stanley cut their price objective on shares of Cryoport from $8.00 to $7.00 and set an “equal weight” rating for the company in a report on Monday, May 5th. Finally, Guggenheim reiterated a “buy” rating and issued a $10.00 price objective on shares of Cryoport in a report on Wednesday, April 16th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $11.00.

Cryoport Stock Down 2.4%

CYRX stock opened at $6.98 on Monday. The company has a market cap of $349.96 million, a price-to-earnings ratio of -2.07 and a beta of 1.92. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. Cryoport has a 12 month low of $4.58 and a 12 month high of $14.21. The firm has a 50-day moving average of $5.90 and a two-hundred day moving average of $6.87.

Institutional Trading of Cryoport

Several hedge funds have recently made changes to their positions in the company. Franklin Resources Inc. grew its stake in shares of Cryoport by 0.4% in the 4th quarter. Franklin Resources Inc. now owns 387,131 shares of the company’s stock valued at $3,012,000 after buying an additional 1,512 shares during the period. Rhumbline Advisers grew its stake in shares of Cryoport by 2.9% in the 4th quarter. Rhumbline Advisers now owns 63,284 shares of the company’s stock valued at $492,000 after buying an additional 1,764 shares during the period. Point72 Asia Singapore Pte. Ltd. boosted its position in shares of Cryoport by 148.7% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock worth $28,000 after purchasing an additional 2,120 shares during the period. Sierra Summit Advisors LLC boosted its position in shares of Cryoport by 5.0% during the 1st quarter. Sierra Summit Advisors LLC now owns 45,060 shares of the company’s stock worth $274,000 after purchasing an additional 2,150 shares during the period. Finally, Nebula Research & Development LLC boosted its position in shares of Cryoport by 21.6% during the 4th quarter. Nebula Research & Development LLC now owns 12,442 shares of the company’s stock worth $97,000 after purchasing an additional 2,207 shares during the period. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Insider Activity

In other news, CEO Jerrell Shelton sold 4,620 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $6.29, for a total value of $29,059.80. Following the completion of the sale, the chief executive officer now owns 765,399 shares of the company’s stock, valued at $4,814,359.71. This represents a 0.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders sold a total of 19,830 shares of company stock valued at $118,353 in the last 90 days. Company insiders own 10.00% of the company’s stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.